Over the past few decades, the Non-Small Cell Lung Cancer market has observed significant growth in the entry of new treatment options in the market. Similarly, several of the biomarkers have emerged as efficacious treatments option for the NSCLC. Currently, some rare biomarkers for Non-Small Cell Lung Cancer (NSCLC) include METex14 skipping alterations, ALK rearrangements, HER-2 mutations, RET rearrangements, and many more.
Globally, in order to grab the market share, some of the key pharma companies such as Apollomics, Merck, Eli Lilly and Company, Novartis, and others are exploring the potential of biomarkers for the treatments of Non-Small Cell Lung Cancer. According to Delveinsight, these therapies are going to revolutionize the treatment of lung cancers. Along with the growth in the market size, the survival outcomes and quality of life are also expected to get better in the coming years.
For more details, visit: Biomarkers in Non-small Cell Lung Cancer (NSCLC) Market